News

Instant vaccine in the making
Enlarge image

ResearchGermany

Instant vaccine in the making

26.11.2012 - Immunologists from Germany prove that messenger RNA vaccines work in mice, ferrets and pigs. Translation to humans would speed up flu control.

The idea sounds compelling: Instead of injecting peptide parts or complete proteins to trigger immune reactions, future vaccines could consist of messenger RNA molecules. Scientists from the Friedrich-Loeffler-Institut and the biotech enterprise CureVac GmbH (both from Tübingen, Germany) as well as from a branch of Friedrich-Loeffler-Institut on an island in the Baltic Sea near Greifswald, showed that immunisation with mRNA works thus far in mice, ferrets and pigs. The corresponding study was published online on 25 November by Nature Biotechnology. Lead author Lothar Stitz from Greifwald and colleagues report that the resulting immune responses were similar or even stronger than those provoked by commercially available vaccines.

Producing conventional vaccines is a time-consuming process. If Stitz’ approach also works in humans, flu vaccines could be designed and made within weeks instead of months. Hence, pandemics could be brought under control much more easily. What is more, mRNA vaccines in general are characterised by superior stabilities at high temperatures and by improved efficacy in young and old mice. These features could make a difference as it is mostly the elderly and children who suffer most from flu casualties.

The results strengthen German Curevac GmbH, the manufacturer of mRNA-coded antigens. Only in September, the biotech set a German record by closing the biggest financing round of a German biotech ever (€80m).

© eurobiotechnews.eu/ml

http://www.european-biotechnology-news.com/news/news/2012-04/instant-vaccine-in-the-making.html

BusinessGermany

24.08.2014 Germany's Morphosys is licensing a preclinical bi-specific antibody for the treatment of prostate cancer from Emergent Biosolutions. The US developer will rake in up to €138m for the commercialisation rights to the compound.

BusinessUK

20.08.2014 Biopharmaceutical contract manufacturer Fujifilm Diosynth Biotechnologies is expanding its cell culture manufacturing capacity further with a new 2,000l single-use bioreactor at the company’s site in Billingham, UK.

BusinessEUGermanyUK

15.08.2014 Some of Europe’s biggest pharma companies are competing in a bidding war for US biotech Intermune Inc., Bloomberg reports, citing insider reports as the source.

ResearchEUGermanyUK

13.08.2014 The Ebola epidemic is still raging on in West Africa and thus far there is

neither vaccine nor cure for the viral disease. The only flickers of hope:

an experimental antibody serum and an early-stage vaccine.

BusinessFrance

11.08.2014 Will Sanofi succeed where Pfizer failed? The French pharmaceutical company has taken on the commercialisation of Mannkind Corporation’s inhaled insulin product Afrezza.

ResearchSwedenGermany

08.08.2014 Boehringer Ingelheim is walking away from Swedish Orexo's prostaglandin inhibition project OX-MPI. Germany's largest researching pharmaceutical company had been responsible for the project's research and development since 2005.

ResearchSwitzerlandDenmark

06.08.2014 Roche is re-expanding its involvement in RNAi technologies. The Swiss pharmaceutical company will pay up to €335m for the acquisition of the Danish company Santaris Pharma A/S.

ResearchUKSwitzerland

03.08.2014 In its efforts to become the leading country in genetic research, the UK has attracted investments worth more than £300m (€376m) to map 100,000 human genomes by 2017.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • MOLOGEN7.85 EUR5.65%
  • CYTOS0.26 CHF4.00%
  • PAION2.48 EUR2.06%

FLOP

  • 4SC1.25 EUR-2.34%
  • FORMYCON6.75 EUR-1.75%
  • VITA 343.75 EUR-1.57%

TOP

  • SANTHERA83.50 CHF21.8%
  • MAGFORCE6.90 EUR10.8%
  • BB BIOTECH140.45 EUR5.1%

FLOP

  • WILEX2.36 EUR-25.1%
  • MOLOGEN7.85 EUR-19.5%
  • VITA 343.75 EUR-17.6%

TOP

  • SANTHERA83.50 CHF3695.5%
  • CO.DON2.61 EUR226.2%
  • PAION2.48 EUR188.4%

FLOP

  • CYTOS0.26 CHF-93.5%
  • MEDIGENE4.48 EUR-68.1%
  • MERCK KGAA66.20 EUR-43.4%

No liability assumed, Date: 26.08.2014